Although the level of prostaglandin (PG) D 2 in cerebrospinal fluid (CSF) affects the action of D-type prostanoid receptors that promote physiological sleep, the regulatory system of PGD 2 clearance from the CSF is not fully understood. The purpose of this study was to investigate PGD 2 elimination from the CSF via the blood-CSF barrier (BCSFB). The in vivo PGD 2 elimination clearance from the CSF was 16-fold greater than that of inulin, which is considered to reflect CSF bulk flow. This process was inhibited by the simultaneous injection of unlabeled PGD 2 . The characteristics of PGD 2 uptake by isolated choroid plexus were, at least partially, consistent with those of PG transporter (PGT) and organic anion transporter 3 (OAT3). Studies using an oocyte expression system showed that PGT and OAT3 were able to mediate PGD 2 transport with a Michaelis-Menten constant of 1.07 and 7.32 M, respectively. Reverse transcription-polymerase chain reaction and immunohistochemical analyses revealed that PGT was localized on the brush-border membrane of the choroid plexus epithelial cells. These findings indicate that the system regulating the PGD 2 level in the CSF involves PGT-and OAT3-mediated PGD 2 uptake by the choroid plexus epithelial cells, acting as a pathway for PGD 2 clearance from the CSF via the BCSFB.
Introduction
Prostaglandin (PG) D 2 is an endogenous sleep-promoting substance that regulates physiological sleep, both non-rapid eye movement and rapid eye movement sleep, through Dtype prostanoid receptor 1 (DP 1 receptor) (Huang et al., 2007) . Because the DP 1 receptors are localized predominantly in the arachnoid trabecular cells in the ventral surface of the rostal basal forebrain (Mizoguchi et al., 2001) , which faces the CSF, the CSF concentration of PGD 2 will be a key determinant of the action of DP 1 receptors. Indeed, infusion of PGD 2 into the lateral ventricle increases the amount of non-rapid eye movement sleep in a dose-dependent manner in wild-type mice but not DP 1 receptor knockout mice (Mizoguchi et al., 2001) . In unanesthetized conscious rats, the CSF concentration of PGD 2 exhibits a significant circadian fluctuation with a peak (1197 pg/ml; 3.4 nM) at 2:00 PM and a minimum (438 pg/ml; 1.2 nM) at 6:00 AM (Pandey et al., 1995) . These lines of evidence imply that regulatory systems for the generation and/or elimination of PGD 2 in the CSF produce a circadian rhythm.
The rates of generation and elimination of PGD 2 in the CSF seem to be well balanced to maintain PGD 2 levels in the CSF. It has been proposed that PGD 2 is generated from PGH 2 mainly by lipocalin-type prostaglandin D synthetase (L-PGDS) and released into the CSF (Qu et al., 2006) . PGD 2 is also transported from the circulating blood to the brain across the blood-brain barrier (Suzuki et al., 1986) . However, a clearance system for PGD 2 from the CSF would be essential for regulating PGD 2 levels in the CSF. In the brain, it is unlikely that prostaglandins are effectively inactivated, be-cause there is little expression and activity of 15-hydroxyprostaglandin dehydrogenase, the rate-limiting enzyme for prostaglandin catabolism, in the adult brain (Alix et al., 2008) . It is thus conceivable that the primary pathway for removing PGD 2 from the CSF is the CSF-to-blood vectorial transport across the blood-CSF barrier (BCSFB), which is formed by the complex tight junctions of choroid plexus epithelial cells in the ventricle . In support of this notion, it has been reported that the choroid plexus takes up PGF 2␣ via a saturable transport process (DiBenedetto and Bito, 1986) .
Cellular transport of PGs is mediated by several transporters: organic anion transporter (OAT) (OAT/SLC22) (Kimura et al., 2002) , organic cation transporter (OCT) (OCT/SLC22) (Kimura et al., 2002) , and organic anion transporting polypeptide (oatp) (OATP/SLCO) (Kanai et al., 1995; Cattori et al., 2001) . Among high-affinity transporters for PGs with nanomolar K m values, OAT3 (SLC22A3) (Nagata et al., 2002) and prostaglandin transporter (PGT) (PGT/SLCO2A1) (Kis et al., 2006) are expressed in the choroid plexus. OAT3 recognizes PGE 2 with a K m value of 345 nM (Kimura et al., 2002) , whereas PGT transports various prostaglandins, including PGE 1 , PGE 2 , and PGF 2␣ ,with a K m value of 70 to 104 nM (Kanai et al., 1995) . Because there is an overlap in substrates between PGT and OAT3, a combination of these transporters at the BCSFB should act as a regulatory system for PGD 2 levels in the CSF.
The purpose of the present study was to investigate the elimination of PGD 2 from the CSF across the BCSFB by using intracerebroventricular administration and the uptake by isolated choroid plexus and to identify which transporters are responsible for PGD 2 transport by using an expression system involving Xenopus laevis oocytes.
Materials and Methods
Animals. Adult male ddY mice (25-30 g), Wistar rats (260 -280 g), and female Hartley guinea pigs (300 -350 g) were purchased from Japan SLC (Hamamatsu, Japan). Mature female X. laevis oocytes were purchased from Kato-S-Science (Chiba, Japan). They were maintained in a controlled environment, and all experiments were approved by the Animal Care Committee of the University of Toyama. To minimize the diurnal variations, the transport analyses and tissue sampling were conducted from noon to 7:00 PM.
Reagents. [5, 6, 8, 9, 12, 14, In Vivo PGD 2 Efflux from the CSF after Intracerebroventricular Administration.
[ 3 H]PGD 2 elimination from the CSF after intracerebroventricular administration was studied by using the method described previously (Tachikawa et al., 2008a,b) . Male Wistar rats were anesthetized by intraperitoneal injection of pentobarbital (50 mg/kg body weight), and their heads were fixed in a stereotaxic apparatus (Narishige, Tokyo, Japan). A hole was drilled in the skull, 1.5 mm to the left and 0.5 mm posterior to the bregma, into which a needle was fixed as a cannula for injection. A cerebroventricular dose of [ 3 H]PGD 2 (0.4 Ci/rat) and [ 14 C]inulin (0.005 Ci/rat) dissolved in 10 l of extracellular fluid buffer containing 122 mM NaCl, 25 mM NaHCO 3 , 3 mM KCl, 0.4 mM K 2 HPO 4 , 1.4 mM CaCl 2 , 1.2 mM MgSO 4 , 10 mM D-glucose, and 10 mM HEPES was administered to the left lateral ventricle through the cannula. At designated times, CSF (50 -100 l) was withdrawn by cisternal puncture. The remaining radioactivity in the CSF specimens was determined by using a liquid scintillation spectrophotometer (LSC-5000; Aloka, Tokyo, Japan). The kinetic parameters for the elimination of [ 3 H]PGD 2 and [ 14 C]inulin were determined from Eq. 1 by using the nonlinear least-square regression analysis program MULTI (Yamaoka et al., 1986) :
where C CSF (t), V d , and k el are the CSF concentration at time t, the volume of CSF, and the elimination rate constant, respectively. As indicated in Fig. 1a Fig. 1a were ϳ500% dose/ml CSF, the volume of CSF in which [
14 C]inulin can be initially distributed was determined to be approximately 200 l. This volume is in close agreement with the total CSF volume in rats as reported previously (Cserr and Berman, 1978 ). An apparent elimination clearance was determined by multiplying k el by
HPLC Analysis. At 2 min after intracerebroventricular administration of [ 3 H]PGD 2 (2 Ci/rat), the CSF was collected via cisternal puncture. The CSF was mixed with acetonitrile and acetic acid each at a concentration of 45% (v/v) and 0.1% (v/v), respectively. The mixture was centrifuged at 12,000g for 5 min at 4°C, and the supernatant was collected. Then, 20 l was subjected to HPLC analysis. The HPLC system consisted of a pump (EP-300; Eicom, Kyoto, Japan) and a column oven (ATC-300; Eicom). The HPLC analytical column was an Inertsil ODS-2 column (5 m, 4.6 ϫ 150 mm; GL Sciences, Tokyo, Japan). The mobile phase (acetonitrile/acetic acid/ water, 45:0.1:55, v/v/v) was pumped through the column at a rate of 1.0 ml/min at 20°C. Samples of eluate were collected in scintillation counting vials, and the 3 H radioactivity in each fraction (1.0 ml) was determined in a liquid scintillation counter (LSC-5000; Aloka).
PGD 2 Uptake using Freshly Isolated Rat Choroid Plexus. The uptake of [ 3 H]PGD 2 by rat choroid plexus was examined by using the centrifugal filtration method described previously (Tachikawa et al., 2008a,b) . The rats were decapitated, and the choroid plexus was isolated from the lateral ventricles and incubated at 37°C for 1 min in 300 l of extracellular fluid buffer. (Mori et al., 2003) . Defolliculated oocytes were injected with 23 nl of water or the capped cRNA (50 -100 ng) and incubated at 18°C in freshly prepared standard oocyte saline solution containing 100 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM HEPES, 25 g/ml gentamycin, 2.5 mM pyruvic acid, and 1% bovine serum albumin, pH 7.5. The standard oocyte saline solution used to incubate the oocytes was replaced daily with fresh solution. Experiments were performed after incubation for 4 to 6 days. An uptake study using PGT-and OAT3-expressing X. laevis oocytes was performed as described previously (Mori et al., 2003) . The oocytes injected with PGT cRNA or OAT3 cRNA were preincubated with 500 l of ND96 solution containing 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , and 5 mM HEPES, pH 7.4, for 20 min at 20°C before the uptake experiment. The uptake experiment was initiated by replacing the ND96 solution with 200 l of the same solution containing 1.2 nM [ 3 H]PGD 2 and terminated by the addition of ice-cold ND96 solution after incubation for a designated time at 20°C. Oocytes were then washed four times with ice-cold ND96 solution and solubilized in 5% standard oocyte saline solution, and the accumulated radioactivity was determined in a liquid scintillation counter (LSC-5000; Aloka). For the inhibition study, the uptake of 1.25 nM [ 3 H]PGD 2 was measured in the presence or absence of various unlabeled compounds in ND96 solution. The distribution volume of [ 3 H]PGD 2 per oocyte (l/oocyte) was calculated as the amount of [ 3 H]PGD 2 accumulated per oocyte (dpm/oocyte) divided by the medium concentration of [ 3 H]PGD 2 (dpm/l). The specific uptake was calculated by subtracting the uptake by waterinjected oocytes from the uptake by PGT-or OAT3-expressing oocytes.
Kinetic Analyses. The kinetic parameters for PGD 2 uptake by Xenopus oocytes expressing PGT and OAT3 were obtained from Eq. 2:
where V is the uptake rate of PGD 2 , S is the PGD 2 concentration in the medium, K m is the Michaelis-Menten constant, and V max is the maximum uptake rate. To obtain kinetic parameters, the equation was fitted by using the iterative nonlinear least-squares regression analysis program MULTI (Yamaoka et al., 1986) .
RT-PCR Analysis. Total RNA was isolated from mouse choroid plexus and rat brain and lung by using TRIzol reagent (Invitrogen, Carlsbad, CA) as described by the manufacturer. The RNA was reverse-transcribed by using oligo(dT) primer and ReverTraAce (Toyobo Engineering, Osaka, Japan). PCR was performed by using ExTaq DNA polymerase (Takara, Kyoto, Japan) with the following thermal cycle program: 30 cycles of 94°C for 30 s, 60°C for 30 s, 72°C for 1 min, and a final period of 72°C for 10 min. The sequences of the specific primers for mouse PGT (GenBank accession number AF323958) were as follows: the sense sequence was 5Ј-CATCTTCGT-CAGCTACTTCGGC-3Ј and the antisense sequence was 5Ј-CACAT-GCTGCTGGTCTCCTTCT-3Ј. The PCR products were separated by electrophoresis on an agarose gel in the presence of ethidium bromide and visualized under ultraviolet light. The molecular identify of the resultant product was confirmed by sequence analysis using a DNA sequencer (ABI PRISM 3100; Applied Biosystems, Foster City, CA).
Antibodies. Polyclonal antibodies to PGT and L-PGDS were raised against amino acid residues 122 to 161 of mouse PGT (GenBank accession number AF323958) and amino acid residues 150 to 189 of mouse L-PGDS (GenBank accession number NP032989). The polypeptides were expressed as glutathione transferase fusion proteins using the pGEX4T-2 plasmid vector (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK). The fusion protein was purified with glutathione-Sepharose 4B (GE Healthcare), emulsified with Freund's complete adjuvant (Difco, Detroit, MI), and injected subcutaneously into female Hartley guinea-pigs at 2-week intervals. Two weeks after the sixth injection, affinity-purified antibodies were prepared, first using protein G-Sepharose (GE Healthcare) and then using antigen peptides coupled to cyanogen bromide-activated Sepharose 4B (GE Healthcare). For the preparation of affinity media, polypeptides free of glutathione transferase were obtained by elution of the cleaved polypeptide after in-column thrombin digestion of fusion proteins bound to glutathione-Sepharose 4B.
Immunoblotting. Mouse lung and choroid plexus were homogenized in a buffer containing 10 mM HEPES, 1 mM EDTA, 1 mM EGTA, 320 mM sucrose, 1 mM phenylmethylsulfonyl fluoride, and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO), pH 7.4. Mouse brain was homogenized in a radioimmunoprecipitation assay buffer containing 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% nonidet P-40, 0.1% SDS, 1% sodium deoxycholate, and a protease inhibitor cocktail (Sigma-Aldrich). The homogenates were centrifuged at 10,000g for 15 min. The supernatants were then obtained as whole lysate protein samples or further centrifuged at 100,000g for 60 min to obtain a crude membrane fraction from the pellets. The protein concentration was determined by the Bradford method using a DC Protein Assay kit (Bio-Rad Laboratories, Hercules, CA). Protein samples (50 g per lane) were fractionated by 10% SDS-polyacrylamide gel electrophoresis and electroblotted onto a nitrocellulose membrane. The blotted membrane was incubated with an affinity-purified PGT antibody at 0.1 g/ml or affinity-purified L-PGDS antibody at 0.5 g/ml in Tris-buffered saline (25 mM TrisHCl, pH 8.0 and 125 mM NaCl, pH 7.4) containing 0.1% Tween 20 and 4% skimmed milk, and visualized with an enhanced chemiluminescence kit (GE Healthcare).
Immunohistochemistry. Preparation of brain paraffin sections (5 m) using a sliding microtome (SM2000R; Leica Wetzlar, Nussloch, Germany) and immunohistochemistry were performed as described previously (Tachikawa et al., 2004) . In brief, for immunofluorescence, sections were immunoreacted overnight with guinea pig antibody to PGT or L-PGDS (2 g/ml) singly or in combination with rabbit glucose transporter 1 (GLUT1) antibody (0.5 g/ml; Sakai et al., 2003) and mouse Na ϩ , K ϩ -ATPase antibody (2 g/ml; Millipore Corporation, Billerica, CA). Subsequently, they were incubated with species-specific Alexa Fluor 488-conjugated (Invitrogen) and Cy3-conjugated (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) secondary antibodies for 2 h. Photographs were taken with a confocal laser scanning microscope (TCS-SP5; Leica).
Statistical Analysis. Unless otherwise indicated, all data are presented as the mean Ϯ S.E.M. The kinetic parameters are presented as the mean Ϯ S.D. An unpaired, two-tailed Student's t test was used to determine the significance of differences between two group means. One-way analysis of variance followed by the modified Fisher's least-squares difference method was used to assess the statistical significance of differences among means of more than two groups.
Results
Elimination of PGD 2 from Rat CSF after Intracerebroventricular Administration. Figure 1a shows 14 C]inulin elimination from the CSF were estimated to be 1.15 and 17.5 min, respectively. The elimination clearance of PGD 2 from the CSF (124 l/min) was approximately 16-fold higher than that of inulin (7.80 l/min). The elimination clearance of inulin was close to the CSF bulk flow rate (2.9 l/min) obtained by Suzuki et al. (1985) . The simultaneous injection of unlabeled PGD 2 with [ 3 H]PGD 2 at a CSF concentration of 100 M resulted in a 3.4-fold increase in the residual concentration of [ 3 H]PGD 2 (340% dose/ml CSF) compared with that in the absence of PGD 2 (101% dose/ml CSF) at 20 min. Fig. 1, b Eguchi et al. (1992) , the additional peak was presumably considered to correspond to PGF 2␣ . Because the sum of radioactivity eluted from 6.5 to 9.5 min, which corresponds to intact uptake by the isolated choroid plexus exhibited a time-dependent increase linearly for up to 1 min of incubation with an initial uptake rate of 4.47 Ϯ 0.56 l/(min ⅐ l choloid plexus) (Fig. 1d) . To characterize the transporters involved in [ 3 H]PGD 2 uptake by the isolated choroid plexus, the inhibitory effects of various compounds on the [ 3 H]PGD 2 uptake were investigated (Table 1) . PGD 2 and PGB 1 produced 78 and 85% inhibition of the [ 3 H]PGD 2 uptake at a concentration of 1 mM. Bromocresolgreen, an inhibitor of PGT, inhibited the uptake by 79% at a concentration of 1 mM. The uptake was also inhibited by OAT3 substrates and/or inhibitors, such as dehydroepiandrosterone-3-sulfate (DHEAS), indomethacin, benzylpenicillin, and probenecid, by 23 to 75%. In contrast, L-lactic acid had little effect on the uptake. These results suggest the involvement of PGT and OAT3 in PGD 2 uptake by the isolated rat choroid plexus.
Characteristics of PGT and OAT3-Mediated [
H]PGD 2 Uptake in Mouse PGT-Expressing and Rat OAT3-Expressing Xenopus Oocytes. Although the [
3 H]PGD 2 uptake study using the isolated choroid plexus suggests the involvement of PGT and OAT3, the contribution of each transporter to the PGD 2 uptake remains unknown. To determine the characteristics of PGT-and OAT3-mediated PGD 2 transport, [
3 H]PGD 2 uptake was studied with PGT-and OAT3-expressing oocytes (PGT/oocytes and OAT3/oocytes, respectively). [ 3 H]PGD 2 was taken up in a time-dependent manner by PGT/oocytes (Fig. 2a) and OAT3/oocytes (Fig. 3a) , and the uptake by these oocytes was several-fold higher than in water-injected oocytes. As shown in Figs. 2b and 3b, PGD 2 uptake by PGT/oocytes and OAT3/oocytes exhibited saturable kinetics with a K m of 1.07 Ϯ 0.32 M and a V max of 9.36 Ϯ 0.71 pmol/(h ⅐ oocyte), and a K m of 7.32 Ϯ 1.27 M and a V max of 2.14 Ϯ 0.28 pmol/(h ⅐ oocyte), respectively. The inhibitory effects of various compounds on PGT-and OAT3-mediated [ 3 H]PGD 2 uptake were examined (Table 2) . Bromocresolgreen, at a concentration of 
Expression and Localization of PGT in the Choroid
Plexus. RT-PCR gave one amplified product at the expected size of 255 bp in the mouse choroid plexus as well as the brain and lung used as a positive control for PGT expression (Fig. 4) . The nucleotide sequences of the products were identical with that of mouse PGT (GenBank accession number AB103401). The expression and localization of PGT protein in the choroid plexus were characterized with guinea pig PGT antibody. Immunoblot analysis showed a single band at ϳ55 to 65 kDa, which was detected in the lung used as a positive control for PGT expression and the choroid plexus (Fig. 5, a and b) . One possible explanation for the difference in the molecular size of PGT between the lung and choroid plexus is the glycosylation between the lung and choroid plexus PGT. By using immunohistochemical techniques, the PGT antibody labeled the choroid plexus (Fig. 6a) . PGT immunofluorescence was intense on the CSF side membrane of the choroid plexus epithelial cells (Fig. 6c) . The bands and immunochemical staining were abolished with the use of antibody with preabsorbed antigen peptides (100 g/ml), indicating the specificity of PGT antibody (Figs. 5a and 6d) . By double immunofluorescence for Na ϩ , K ϩ -ATPase, a brush-border membrane marker of choroid plexus epithelial cells, the PGT immunoreactivities showed extensive overlapping with those of Na ϩ , K ϩ -ATPase (Fig. 6e) . In contrast, they were negative for GLUT1, a basolateral membrane marker of choroid plexus epithelial cells (Fig. 6f) . These results indicate that PGT is localized on the brush-border membrane of choroid plexus (Fig. 5c) , which is consistent with previous results (Urade et al., 1989) . The band was abolished with the use of antibody with preabsorbed antigen peptides (100 g/ml), indicating the specificity of L-PGDS antibody (Fig. 5c ). The L-PGDS antibody strongly labeled the leptomeninges (Fig. 6b) .
Discussion
In the present study, our findings indicate that a regulatory system of the PGD 2 level in the CSF involves PGT-and OAT3-mediated PGD 2 uptake by the choroid plexus epithelial cells, acting as a pathway for PGD 2 elimination from the CSF.
[ 3 H]PGD 2 , after intracerebroventricular administration, was removed from the CSF most likely as the intact form with a 16-fold greater elimination clearance than that of [ 14 C]inulin, which is considered to reflect the CSF bulk flow (Fig. 1a) . The rapid elimination of [ 3 H]PGD 2 from the CSF was inhibited by simultaneous injection of unlabeled PGD 2 at a CSF concentration of 100 M (Fig. 1a) , suggesting active efflux transport of PGD 2 from the CSF. This is in close agreement with a previous report demonstrating active elimination of PGF 2␣ from rabbit CSF using ventriculo-cisternal perfusions . To evaluate the role of the BCSFB in PGD 2 elimination from CSF, [ 3 H]PGD 2 uptake by the freshly isolated rat choroid plexus was investigated ( Fig.  1d (Fig. 1d) . This indicates that the BCSFB contributes to the carrier-mediated efflux transport of PGD 2 from the CSF. The elimination clearance of PGD 2 from the CSF via the BCSFB was estimated from the initial uptake rate of PGD 2 by the isolated choroid plexus and found to be 26.8 l/min per rat [4.47 l/(min⅐l choroid plexus) ϫ 6 l (the volume of total rat choroid plexus per rat); Ogawa et al., 1994] . The PGD 2 efflux transport via the BCSFB makes a 21.6% contribution to the total PGD 2 elimination clearance from the CSF in vivo (124 l/min per rat). Because the elimination clearance of inulin from the CSF was 7.80 l/min per rat, i.e., 6.29% of the total PGD 2 elimination clearance from the CSF, the contribution of the CSF bulk flow and diffusion into the brain interstitial space seems to be limited. It has been reported that Slco2b1 (moat1) transports PGD 2 and is expressed in the brain parenchymal cells (Nishio et al., 2000) . It would raise another possibility that Slco2b1-mediated uptake by brain parenchymal cells is a potential elimination pathway of PGD 2 in the CSF.
The effects of several inhibitors on [ 3 H]PGD 2 uptake by the isolated choroid plexus were examined to identify the transporters involved (Table 1) . Uptake studies with PGT-and OAT3-expressing Xenopus oocytes showed that bromocresolgreen and DHEAS inhibit both PGT-and OAT3-mediated [ 3 H]PGD 2 uptake, whereas benzylpenicillin inhibits only OAT3-mediated [ 3 H]PGD 2 uptake ( Table 2 ). The inhibition ratio of bromocresolgreen and DHEAS for the [ 3 H]PGD 2 uptake (75-80%) by the choroid plexus is greater than that of benzylpenicillin (54%), each at a concentration of 1 mM (Table 1). Furthermore, although the K i value of probenecid for OAT3 was reported to be 4.43 to 20 M (Sugiyama et al., 2001; Nagata et al., 2002 ), probenecid inhibited [ 3 H]PGD 2 uptake by the choroid plexus only by 23% at a concentration of 100 M (Table 1) . Because probenecid at a concentration of 1 mM had little inhibitory effect on PGT-mediated [ 3 H]PGD 2 uptake (Table 2) , it is likely that both PGT and OAT3 are mediators of PGD 2 uptake by the choroid plexus. In support of this notion, the present study indicates that PGT is localized on the brush-border membrane of choroid plexus epithelial cells (Fig. 6) . It should also be noted that DHEAS, PGE 2 , and indomethacin are transportable substrates (Cattori et al., 2001 ) and/or inhibitors (Kusuhara et al., 2003) , respectively, of oatp1a5 (Slco1a5), which is localized on the brushborder membrane of choroid plexus epithelial cells (Ohtsuki et al., 2003, 2004) . It is thus intriguing in the future to study the contributions of OAT3, PGT, and oatp1a5.
The K m values of PGD 2 transport mediated by PGT (1.07 M; Fig. 2b ) and OAT3 (7.32 M; Fig. 3b ) are almost three orders of magnitude greater than the CSF concentration of PGD 2 (1-3 nM; Pandey et al., 1995) and PGE 2 (1.2 nM; Gao et al., 2009 ). This suggests that PGT and OAT3 mediate PGD 2 uptake by the choroid plexus epithelial cells without saturation, thus producing continuous removal of PGD 2 from the CSF. Because the circadian fluctuation of the PGD 2 concentration in the CSF ranges from 1 to 3 nM (Pandey et al., 1995) , this may not be caused by the changes in the function of PGT-and OAT3-mediated PGD 2 elimination from the CSF at the BCSFB. It has been reported that the inhibition of PGD 2 -generating enzyme L-PGDS results in a reduction in brain PGD 2 content and suppression of sleep in rats, indicating the crucial role of this enzyme in the regulation of physiological sleep (Qu et al., 2006) . Immunohistochemical analysis reveals that L-PGDS is highly expressed in the leptomeninges facing the CSF (Fig. 6) , which is consistent with previous reports (Urade et al., 1993) . Taking these findings into consideration, it seems likely that the circadian fluctuation in the PGD 2 level in the CSF depends on the local production of PGD 2 , presumably via L-PGDS.
There are two types of CSF-to-blood efflux transport at the BCSFB: 1) influx transport across the brush-border (apical) membrane of choroid plexus epithelial cells from the CSF into the cells and 2) subsequent efflux transport across the basolateral membrane from the cells into the blood. The present findings suggest that PGT and OAT3 on the brushborder membrane are involved in PGD 2 uptake from the CSF into choroid plexus epithelial cells. It has been reported that polarized apical localization of PGT in Madin-Darby canine kidney cells induces a 100-fold increase in apical-to-basal PGE 2 transport . Chan et al. (2002) have reported that PGT-mediated uptake of PGs is coupled to the efflux of intracellular lactate in PGT-overexpressing HeLa cells, which raises the possibility that PGT-mediated concentrative PGD 2 transport in the CSF-to-choroid plexus epithelial cells direction would be produced by the outward lactate gradient, although the lactate gradient in the epithelial cells remains to be determined. Furthermore, the polarized choroid plexus epithelial cells produce transcellular transport of PGE 2 in the apical-to-basolateral direction without inactivation of PGE 2 in the cells (Khuth et al., 2005) . In this regard, PGT and OAT3 on the brush-border membrane of choroid plexus epithelial cells would be a key determinant of the CSF-to-blood PGD 2 efflux transport across the BCSFB. On the other hand, multidrug resistance-associated protein 4 (MRP4)/ATP-binding cassette transporter C4 is localized on the basolateral membrane of choroid plexus epithelial cells (Leggas et al., 2004) and mediates active efflux transport of prostaglandins, such as PGE 1 and PGE 2 , out of the cells (Reid et al., 2003) . Thus, MRP4 would be a potent candidate transporter for mediating PGD 2 efflux transport from the choroid plexus epithelial cells into the blood, although further studies are needed to clarify whether PGD 2 is a substrate of MRP4.
The continuous inhibition of the clearance of PGD 2 at the BCSFB may modify the PGD 2 level in the CSF, thus affecting physiological sleep. Kis et al. (2006) have reported that lipopolysaccharide stimulation diminishes the luminal mem- brane localization of PGT in the cerebral endothelial cells. If this were true for PGT localization in the choroid plexus epithelial cells, PGT-mediated elimination of PGD 2 from the CSF might be reduced under inflammatory conditions. Some commonly used nonsteroidal anti-inflammatory drugs, such as indomethacin and ibuprofen, have been shown to inhibit the transport of PGF 2␣ in the choroid plexus (Bito and Salvador, 1976 ). The present study indicates that indomethacin and diclofenac inhibit OAT3-mediated PGD 2 transport (Table 2). Furthermore, we have found that cefmetazole, cefazolin, ceftriaxone, and cefotaxime, administered intravenously to mice, inhibit [ 3 H]PGE 2 efflux transport from the brain across the blood-brain barrier most likely because of the inhibition of MRP4 (Akanuma et al., 2010) . Thus, the inhibitory effect on the PGT-and OAT3-mediated PGD 2 transport should be taken into consideration in the development of new drugs.
In conclusion, PGT and OAT3 at the BCSFB represent the primary mechanisms for the continuous removal of locally produced PGD 2 from the CSF, thereby regulating PGD 2 levels in the CSF. The present findings thus provide novel insight into the mechanisms of PGs' clearance from the CSF and may be helpful in the development of new therapeutic targets for insomnia.
